Isosorbide mononitrate and Xigduo xr drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported only by a few people who take Isosorbide mononitrate and Xigduo xr together.

The phase IV clinical study analyzes what interactions people who take Isosorbide mononitrate and Xigduo xr have. It is created by eHealthMe based on reports of 5 people who take the same drugs from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Oct, 05, 2022

5 people who take Isosorbide mononitrate and Xigduo xr together, and have interactions are studied.


What is Isosorbide mononitrate?

Isosorbide mononitrate has active ingredients of isosorbide mononitrate. It is often used in angina. eHealthMe is studying from 23,547 Isosorbide mononitrate users for its effectiveness, alternative drugs and more.

What is Xigduo xr?

Xigduo xr has active ingredients of dapagliflozin propanediol; metformin hydrochloride. eHealthMe is studying from 2,217 Xigduo xr users for its effectiveness, alternative drugs and more.

Number of Isosorbide mononitrate and Xigduo xr reports submitted per year:

Isosorbide mononitrate and Xigduo xr drug interactions.

Common Isosorbide Mononitrate and Xigduo Xr drug interactions by gender *:

female:

  1. Chronic kidney disease
  2. Diabetic ketoacidosis
  3. Renal failure
  4. Abdominal discomfort
  5. Blood creatinine increased
  6. Chest pain
  7. Diabetes mellitus
  8. Fluid retention
  9. Organ failure

male:

  1. Blood glucose increased
  2. Contusion
  3. Constipation
  4. Decreased appetite
  5. Dysgeusia
  6. Ill-defined disorder
  7. Weight decreased
  8. Hypoacusis
  9. Injection site haemorrhage
  10. Musculoskeletal discomfort

Common Isosorbide Mononitrate and Xigduo Xr drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Diabetic ketoacidosis
  2. Renal failure
  3. Abdominal discomfort
  4. Blood creatinine increased
  5. Chest pain
  6. Fluid retention
  7. Organ failure
  8. Chronic kidney disease

60+:

  1. Blood glucose increased
  2. Contusion
  3. Hypoacusis
  4. Injection site haemorrhage
  5. Musculoskeletal discomfort
  6. Sciatica
  7. Type 2 diabetes mellitus
  8. Weight increased
  9. Diabetes mellitus

* Approximation only. Some reports may have incomplete information.

Do you take Isosorbide mononitrate and Xigduo xr?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Isosorbide mononitrate and Xigduo xr:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Isosorbide mononitrate interactions:

Browse all interactions between Isosorbide mononitrate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Xigduo xr interactions:

Browse all interactions between Xigduo xr and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on isosorbide mononitrate and dapagliflozin propanediol; metformin hydrochloride (the active ingredients of Isosorbide mononitrate and Xigduo xr, respectively), and Isosorbide mononitrate and Xigduo xr (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Isosorbide mononitrate and Xigduo xr.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: